TABLE 1
Sleep duration (TIB per study day)Baseline vs. sleep restriction condition (P)Drug (P)Interaction (P)
ModafinilPlacebo
5 h10 h5 h10 h
Sleepiness: KSS (1–9 scale)4.65 ± 0.123.23 ± 0.135.31 ± 0.113.61 ± 0.16<0.0001<0.0001<0.0001
Performance: PVT lapses (lapses · test−1 · day−1)4.09 ± 0.452.48 ± 0.375.10 ± 0.730.92 ± 0.18<0.00010.0080.002
Sleep duration: total sleep time (min)268.2 ± 3.5502.2 ± 8.9274.0 ± 1.4467.4 ± 10.8<0.00010.040.001
Slow-wave sleep (min)78.6 ± 3.475.2 ± 5.975.4 ± 3.265.2 ± 7.40.120.500.57
FSIVGTT
    SI [(mU/l)−1 · min−1]4.61 ± 0.555.70 ± 0.884.81 ± 0.786.74 ± 0.940.0010.620.24
    Acute insulin response (mU · l−1 · min)549.2 ± 127.2514.0 ± 106.3532.3 ± 94.1566.7 ± 112.80.300.770.81
    Disposition index2,034.2 ± 231.62,500.6 ± 391.92,079.5 ± 254.12,993.7 ± 431.60.020.460.52
    Glucose tolerance (%/min)−1.984 ± 0.137−2.295 ± 0.160−2.120 ± 0.162−2.465 ± 0.2610.020.430.62
    Glucose effectiveness (min−1)0.017 ± 0.0020.020 ± 0.0020.021 ± 0.0020.023 ± 0.0030.210.150.76
Clamp: M (mg · kg−1 · min−1)6.15 ± 0.667.11 ± 0.866.95 ± 0.817.39 ± 0.790.050.550.69
Salivary cortisol (ng/ml)0.179 ± 0.0170.112 ± 0.0130.180 ± 0.0150.125 ± 0.010<0.00010.700.48
Catecholamines
    Norepinephrine (μg/day)48.0 ± 4.529.7 ± 4.332.5 ± 4.427.5 ± 4.7<0.00010.140.02
    Epinephrine (μg/day)13.5 ± 1.27.0 ± 0.89.0 ± 2.17.4 ± 1.10.0010.290.03
Resting metabolic rate (kcal)1,931.4 ± 77.41,928.6 ± 79.11,851.0 ± 86.41,853.0 ± 116.60.990.560.96
  • Data are means ± SE unless otherwise indicated.